Literature DB >> 15832557

Assessing in vitro combinations of antifungal drugs against yeasts and filamentous fungi: comparison of different drug interaction models.

Joseph Meletiadis1, Paul E Verweij, Debbie T A TeDorsthorst, Jacques F G M Meis, Johan W Mouton.   

Abstract

Non-parametric and parametric approaches of two competing zero-interaction theories--the Loewe additivity and the Bliss independence - were evaluated for analyzing the in vitro interactions of various antifungal drugs. Fifty-one data sets, derived from three drug combinations, tested in triplicate against 17 clinical yeast and mold isolates with a two-dimensional checkerboard microdilution technique, were selected to span from strong synergy to strong antagonism. These were analyzed with the standard FIC index model and modern concentration-effect response surface models: the fully parametric model developed by Greco et al. and the 3-D analysis developed by Prichard et al. The FIC index model is subjective, sensitive to experimental errors and resulted in approximated results and variable conclusions depending on the MIC endpoints determined and interpretation endpoints used. By using the MIC-2 endpoint (lowest drug concentration showing 50% of growth) for calculating the FIC indices, problems due to trailing phenomena were reduced and weak interactions could be detected; higher levels of reproducibility and agreement with the other models were achieved using the MIC-0 and MIC-1 (lowest drug concentration showing 10 and 25% of growth, respectively). High reproducibility was achieved in interpreting the FIC indices when the cutoffs of 0.25 and 4 (for single experiments) and the cutoff of 1 (for replicates) were used for defining the limits of additivity/indifference. Although the fully parametric Greco model did not describe precisely the entire response surface of all antifungal drug interactions, it was able to differentiate synergistic from non-synergistic interactions with a non-unit, reproducible, concentration-independent interaction parameter, including its uncertainty, without requiring replication. The Bliss independence based models resulted in mosaics of synergistic and antagonistic combinations, raising questions about the concentration-dependent nature of antifungal drug interaction. The sum of all statistically significant interactions were used as a summary interaction parameter for the entire response surface, concluding synergy or antagonism when it was positive or negative, respectively. The cutoffs of 100% and 200% were used to distinguish weak and moderate interactions, respectively in 12-16 x 8-12 checkerboard formats. Semi-parametric approaches need particular care as experimental errors are not eliminated from the entire response surface.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15832557     DOI: 10.1080/13693780410001731547

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  41 in total

1.  Multilaboratory testing of two-drug combinations of antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis.

Authors:  Vishnu Chaturvedi; Rama Ramani; David Andes; Daniel J Diekema; Michael A Pfaller; Mahmoud A Ghannoum; Cindy Knapp; Shawn R Lockhart; Luis Ostrosky-Zeichner; Thomas J Walsh; Karen Marchillo; Shawn Messer; Amanda R Welshenbaugh; Cara Bastulli; Noreen Iqbal; Victor L Paetznick; Jose Rodriguez; Tin Sein
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

2.  Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against Aspergillus fumigatus.

Authors:  Joseph Meletiadis; Spyros Pournaras; Emmanuel Roilides; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2009-12-07       Impact factor: 5.191

3.  Multilaboratory testing of antifungal drug combinations against Candida species and Aspergillus fumigatus: utility of 100 percent inhibition as the endpoint.

Authors:  Ping Ren; Ming Luo; Shao Lin; Mahmoud A Ghannoum; Nancy Isham; Dan J Diekema; Michael A Pfaller; Shawn Messer; Shawn R Lockhart; Naureen Iqbal; Vishnu Chaturvedi
Journal:  Antimicrob Agents Chemother       Date:  2014-12-15       Impact factor: 5.191

4.  Repurposing of Aspirin and Ibuprofen as Candidate Anti-Cryptococcus Drugs.

Authors:  Adepemi O Ogundeji; Carolina H Pohl; Olihile M Sebolai
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

5.  In vitro combination of isavuconazole with micafungin or amphotericin B deoxycholate against medically important molds.

Authors:  Aspasia Katragkou; Matthew McCarthy; Joseph Meletiadis; Vidmantas Petraitis; Patriss W Moradi; Gittel E Strauss; Monique M Fouant; Laura L Kovanda; Ruta Petraitiene; Emmanuel Roilides; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2014-08-18       Impact factor: 5.191

6.  Synergistic suppression of dengue virus replication using a combination of nucleoside analogs and nucleoside synthesis inhibitors.

Authors:  Kim Long Yeo; Yen-Liang Chen; Hao Ying Xu; Hongping Dong; Qing-Yin Wang; Fumiaki Yokokawa; Pei-Yong Shi
Journal:  Antimicrob Agents Chemother       Date:  2015-01-26       Impact factor: 5.191

7.  Activities of triazole-echinocandin combinations against Candida species in biofilms and as planktonic cells.

Authors:  Athanasios Chatzimoschou; Aspasia Katragkou; Maria Simitsopoulou; Charalampos Antachopoulos; Elpiniki Georgiadou; Thomas J Walsh; Emmanuel Roilides
Journal:  Antimicrob Agents Chemother       Date:  2011-02-22       Impact factor: 5.191

8.  The in vitro and in vivo efficacy of fluconazole in combination with farnesol against Candida albicans isolates using a murine vulvovaginitis model.

Authors:  Aliz Bozó; Marianna Domán; László Majoros; Gábor Kardos; István Varga; Renátó Kovács
Journal:  J Microbiol       Date:  2016-10-29       Impact factor: 3.422

9.  Optimization of polyene-azole combination therapy against aspergillosis using an in vitro pharmacokinetic-pharmacodynamic model.

Authors:  Maria Siopi; Nikolaos Siafakas; Sophia Vourli; Loukia Zerva; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2015-04-20       Impact factor: 5.191

10.  Synergistic interaction of the triple combination of amphotericin B, ciprofloxacin, and polymorphonuclear neutrophils against Aspergillus fumigatus.

Authors:  Theodouli Stergiopoulou; Joseph Meletiadis; Tin Sein; Paraskevi Papaioannidou; Thomas J Walsh; Emmanuel Roilides
Journal:  Antimicrob Agents Chemother       Date:  2011-09-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.